酷游ku娱乐入口-酷游ku游官网app-ku九州酷游app网址

1 / 3

About Ribo

Established in 2007, Suzhou Ribo Life Science Co. Ltd. is devoted to the advanced oligonucleotide therapeutics in China including siRNA, antisense and aptamer drugs based on proprietary intellectual properties. The core members of the R&D team include top experts in the fields of siRNA biotechnology, nucleic acid chemistry, drug delivery and development, consisting of both overseas returnees and domestic scientists. Ribo is committed to promoting siRNA and other RNA drugs, as well as technology innovation, in order to deliver more precise and efficient therapies to the patients worldwide.

Technological Innovations

Ribo continues to promote innovation of drugs development and the manufacturing process and has established an integrated drug R&D system covering drug design, target validation, drug delivery, quality study, pharmacological, toxicological, and pharmacokinetic evaluation, synthesis of monomers and oligonucleotides, and clinical study.

siRNA delivery technology platform

Oligonucleotide modification for enhanced stability platform

Oligonucleotide therapeutic bioanalysis platform

CMC Development of Oligonucleotide platform

Oligonucleotide monomer platform

Oligonucleotide sequence design and high-throughput screening platform

Pipeline

Driven by independent innovation and international cooperation, Ribo has built up robust R&D pipelines for oligonucleotide targeted at a number of therapeutic areas, such as ophthalmic diseases, metabolic diseases,central nervous system diseases, cancer, and liver diseases, in addition to anti-virus treatment.

SR061

NAION

SR062

Type 2 Diabetes

SR063

Prostate Cancer

SR016

Hepatitis B

SR060

Thrombotic Diseases

SR043

Hyperlipidemia